Metal Complexes For Two-photon Photodynamic Therapy: A Cyclometallated Iridium Complex Induces Two-photon Photosensitization of Cancer Cells Under Near-IR Light. by McKenzie, L. et al.
This is an author produced version of Metal Complexes For Two-photon Photodynamic 
Therapy: A Cyclometallated Iridium Complex Induces Two-photon Photosensitization of 
Cancer Cells Under Near-IR Light..
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/106889/
Article:
McKenzie, L., Sazanovich, I., Baggaley, E. et al. (5 more authors) (2016) Metal Complexes
For Two-photon Photodynamic Therapy: A Cyclometallated Iridium Complex Induces 
Two-photon Photosensitization of Cancer Cells Under Near-IR Light. Chemistry - A 
European Journal. ISSN 0947-6539 
https://doi.org/10.1002/chem.201604792
This is the peer reviewed version of the following article: McKenzie, L. K., Sazanovich, I. 
V., Baggaley, E., Bonneau, M., Guerchais, V., Williams, J. A. G., Weinstein, J. A. and 
Bryant, H. E. (2016), Metal Complexes for Two-Photon Photodynamic Therapy: A 
Cyclometallated Iridium Complex Induces Two-Photon Photosensitization of Cancer Cells 
under Near-IR Light. Chem. Eur. J., which has been published in final form at 
http://doi.org/10.1002/chem.201604792. This article may be used for non-commercial 
purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
Supported by
A Journal of
Accepted Article
	
 	
	

			
	
 

		!"#$%

 $&'(%)*(+	,-%%	(
&.	-(/012(23		(
4	3(5	+-
, *
		%( %( 	,	
  	/ #6/#78&	,	,
%9%	:,; 69:7%*,	8/#		,
,		+	/,	,  
 	 	 %8#	,
 /#    ;	 ,  ,	    ,	
  8,	 
 	8
		
 	
		<=8<==>?8>=<@=ABC>

 ??88%?<=8<==>?8>=<@=ABC>
 1 
Metal Complexes For Two-photon Photodynamic Therapy: A Cyclometallated 
Iridium Complex Induces Two-photon Photosensitization of Cancer Cells Under 
Near-IR Light 
Luke K. McKenzie1,2,  Igor V. Sazanovich1,2,¤, Elizabeth Baggaley2, Mickale 
Bonneau3,4, Vronique Guerchais4, J. A. Gareth Williams3, Julia A. Weinstein2* and 
Helen E. Bryant1* 
1Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 
2RX, UK 
2Department of Chemistry, University of Sheffield, Sheffield S3 7HF, UK 
3Department of chemistry, Durham University, Durham DH1 3LE, UK 
 
4UMR CNRS 6226, Universit de Rennes 1, Institut des Sciences Chimiques de 
Rennes, Campus de Beaulieu, 35042 Rennes, France 
 
¤Current address: Harwell Science Campus, OX11 0QX, UK 
 
CORRESPONDING AUTHORS INFORMATION 
*Correspondence should be addressed to HB, tel. +44 (0)114 2759040, fax: +44 114 
2795320, E-mail: h.bryant@sheffield.ac.uk or JW, tel: +44 (0)114 2229408, fax: +44-
(0)114-22-29436, E-mail: julia.weinstein@sheffield.ac.uk 
 
  
10.1002/chem.201604792Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
 2 
ABSTRACT 
Photodynamic therapy (PDT) uses photosensitizers (PS) which only become cytotoxic 
upon light-irradiation. Transition metal complexes are highly promising PS due to 
long excited state lifetimes, and photostability. However, these complexes usually 
absorb higher-energy UV/Visible light, whilst the optimal tissue transparency is in the 
lower-energy NIR region. Two-photon excitation (TPE) can overcome this 
dichotomy, with simultaneous absorption of two lower-energy NIR-photons 
populating the same PS-active excited state as one higher-energy photon.   
 We introduce two low-molecular weight, long-lived and photostable iridium 
complexes of the [Ir(N^C)2(N^N)]
+ family with high TP-absorption, which localise to 
mitochondria and lysosomal structures in live cells. The compounds are efficient PS 
under 1-photon irradiation (405 nm) resulting in apoptotic cell death in diverse cancer 
cell lines at low light doses (3.6 J cmÐ2), low concentrations, and photoindexes of up 
to >555. Remarkably 1 also displays high PS activity killing cancer cells under NIR 
two-photon excitation (760 nm), which along with its photostability indicates 
potential future clinical application.  
 
Main text 
Photodynamic therapy (PDT) is a light-activated treatment offering reduced side 
effects compared to traditional therapy[1]. The PDT agent, a photosensitizer (PS), is 
only activated upon targeted irradiation by light of a PS-specific wavelength which 
promotes the PS to its excited, high-energy state (*PS).  
In oxygen-dependent PDT, cellular oxygen and *PS interactions allow excited-state 
energy transfer, regenerating the ground state of the PS and producing reactive 
oxygen species (ROS) including singlet oxygen (1O2), with subsequent reactions with 
the intracellular components leading to cell death. Targeted intracellular localisation 
of the PS is important for maximum effect with organelles situated nearest to *PS 
being the most affected.[2] 
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The photophysical properties of many transition metal complexes make them ideal PS 
candidates. Their key advantage over organic molecules is the heavy atom effect 
which favours fast singlet to triplet intersystem crossing (ISC). The longer lifetimes 
which result from ISC lead to high yields of 1O2 and/or other ROS. The ease of 
chemical modification and photostability adds to the appeal of these complexes. 
Accordingly, an increasing number of transition metal complexes have been 
investigated for use in PDT including those of Pt(IV), Pt(II), Ru(II), Re(I)[3] and 
Ir(III).[4] 
 
One limitation to the clinical use of metal complexes investigated for PDT has been 
their absorption of light in the UV/Vis region, whilst the optimal tissue penetration 
window is 700 Ð 900 nm. Two-photon excitation (TPE), or two-photon PDT (TP-
PDT) can overcome this barrier. Compounds with high PDT activity under one-
photon excitation at a particular wavelength in the UV/visible region, should 
theoretically show PDT-activity under TPE in the low-energy NIR region, with the 
simultaneous advantages of the range of relative tissue transparency, increased 
potential depth of tissue penetration, and increased spatial targeting.[5] TP-PDT 
requires high two-photon absorption cross-section and exceptional photostability 
ruling out current clinical photosensitizers. A number transition metal complexes[3c, 6] 
have been developed as two-photon agents, some of which have been shown to 
induce TPE cell killing in vitro using cell cultures.[3c, 6a, 7]  
 
We present here two low-molecular weight, mitochondrial and lysosomal targeting, 
iridium complexes which display good PS activity under one-photon excitation in a 
number of cancer cell lines. Remarkably, one of the complexes is also an efficient PS 
inducing cell death under TPE, and thus displays highly promising results for TP-
PDT.  
 
The new iridium complexes 1 and 2 (Figure 1) are members of the [Ir(N^C)2(N^N)]
+ 
family and closely related to the complex [Ir(ppy)2(pybzH)]
+.[8] 1 and 2 feature bis-
benzimidazole and its N,N-dimethylated derivative, respectively, as the N^N ligand 
(Figure 1). The complexes were prepared as their hexafluorophosphate salts from the 
chloro-bridged dimer [Ir(ppy)2(µ-Cl)]2, by reaction with 2,2'-bisbenzimidazole or 1,1'-
10.1002/chem.201604792Chemistry - A European Journal
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dimethyl-2,2'-bisbenzimidazole (for 1 and 2 respectively), (S3 Ð S5). The absorption 
spectra of 1 and 2 show moderately intense absorbtion bands in the visible region due 
to MLCT transitions (Figure S2). The emission quantum yields are 0.33 and 0.24 
respectively, Emission lifetimes of the order of a microsecond indicate the triplet 
nature of the emissive state. Importantly, the complexes phosphoresce intensely also 
under NIR TPE; and 1 has an appreciable two-photon cross-section of 112 GM at 
760 nm (Figure S2). 
The TPE phosphorescence imaging of 1 and 2 demonstrate cellular uptake (Figure 
S3) with cytoplasmic localisation, similar to that of the previously reported bis-
cyclometallated iridium complexes.[4b, 4d] Co-localisation experiments with organelle-
specific fluorescent dyes demonstrate mitochondrial and lysosomal localisation. 
Within 4 h of exposure, mitochondrial localisation is observed with a PearsonÕs 
correlation coefficient r=0.547 (Figures 2A and S4). Additionally, from 2 h increasing 
lysosomal staining occurs. By 24 h the lysosomal localisation of 1 becomes dominant 
with PearsonÕs correlation coefficients of r=0.387 compared to 0.19 for the 
mitochondrial staining (Figures 2B and S4). 
Cellular uptake was not observed at 4¡C indicating that 1 is actively taken up rather 
than entering cells by passive diffusion (Figure S5). A number of cellular uptake 
pathways were inhibited to determine the uptake route (Figure S5). Only valinomycin, 
which is known to cause an increase in the membrane potential of cells, had an 
inhibitory effect on the uptake of 1 (Figure S5). Thus uptake of 1 appears to largely 
occur via a cell membrane potential-dependent pathway which is consistent with it 
being a singly-charged cation.  
Clonogenic survival assays in the cervical cancer cell line, HeLa demonstrate that 1 
and 2 show high light cytotoxicity giving LD50 values of 0.3 µM and 0.5 µM 
respectively (405 nm, 3.6 J cm-2) (Figure 3 and S6). 1 shows low dark cytotoxicity, 
with an LD50 of >100 µM, whilst 2 shows a much higher dark cytotoxicity, LD50 = 6.2 
µM. Comparative PDT activity of a compound can be estimated by the value of the 
phototoxicity index (PI), PI = LD50
dark/LD50
light.  The lowest estimated PI for 1 in 
HeLa cells is >333, but only 12.4 for 2 due to its high dark cytotoxicity, hence 2 was 
not investigated further. The increased dark toxicity of 2 compared to 1 is likely due 
to the presence of N-Me-groups, which would rule out H-bonding and profoundly 
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affect intermolecular interactions within the cells. 1 also shows photosensitizing 
effects in a number of cancer cell lines (Figure S6), demonstrating the potential broad 
applicability of 1 for PDT.  
 
To evaluate the importance of oxygen in cell killing by 1 and 2, the yield of singlet 
oxygen generation was measured. In air-equilibrated dichloromethane, high Φ(1O2)  
of 42% and 40% for 1 and 2 respectively were determined directly from the emission 
of the 1Δg state of O2 in the NIR (λem 1275 nm) under 355 nm irradiation, 
demonstrating the ability of the complex to generate singlet oxygen. In a cellular 
environment, singlet oxygen immediately reacts with the surroundings, from this 
point of view, the detection of ROS in cells is an important measurement as it 
confirms an increase of cellular ROS concentration in the presence of the 
complex. Here, an approximate 8-fold increase in ROS was detected in cells treated 
with 1 and light (405 nm) compared to cells treated with light alone (Figure S7). 
Efficient intracellular ROS production and 1O2 production in solution are suggestive 
of an oxygen dependant mechanism of cell killing. 
The mechanism of cell death was determined to be apoptosis (Figure S6). It is 
proposed that apoptotic cell death after light treatment is associated with localisation 
of photosensitizers to both the mitochondria and the lysosomes[9]. Here similar 
photosensitizing efficacy is seen when the cells were exposed to light following a 2 hr 
incubation Ð where mainly mitochondrial localisation is seen, or a 24 hr incubation Ð 
where mainly lysosomal localisation is seen (Figure 3). We therefore suggest that 
light induced cell death by 1 may be due to disruption of one or both of these 
organelles, which can trigger apoptotic cell death. 
The photosensitizing activity of 1 under TPE with 760 nm light was investigated in 
HeLa cells (Figure 4). The resulting images show apoptosis (green) and cell death 
(red) induced by TPE photosensitization. The 1-exposed cells within the irradiated 
square clearly show apoptosis/cell death, whilst the surrounding non-irradiated cells 
do not. Little to no killing of cells is seen in the absence of 1 with light power as high 
as 25 mW which under these conditions relates to a dose of 2720 J cmÐ2, this is the 
lower end of light doses reported to date for two-photon photosensitizers.[7a-c] This 
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result therefore demonstrates the potential of 1 as a specific two-photon-activated PS 
at low concentrations and at doses of light that, alone, are not harmful to cells. 
In summary, we introduce two novel small-molecule Ir(III) complexes, which are 
cell-permeable, easy to synthesize, possess long-lived triplet excited states, high linear 
absorption cross sections in the visible range, and high two-photon absorption cross 
sections in the NIR range of the spectrum. 1 has low dark toxicity and is rapidly and 
actively taken up into a diverse range of cancer cell types, where localisation is 
primarily in the mitochondria and lysosomes. High PS activity of 1 has been 
demonstrated in a number of cancer cell lines under one-photon excitation with 405 
nm light, with an impressive PI index of >333 and up to 555 depending on cell line 
(lower limit estimate). Remarkably, 1 is also active in photosensitizing cell death via 
apoptosis under NIR TPE (760 nm), at low concentrations and light doses.  
Overall, the results demonstrate the exciting potential of 1 as a future two-photon 
PDT agent, and illuminate the potential of Ir(III) complexes as TP-PDT agents.   
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SCHEME AND FIGURE LEGENDS 
Figure 1. Complexes 1 and 2.  
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Figure 2. Sub-cellular localisation of 1. U2OS cells following 4 or 24 hour 
incubation with 1 (green), colocalised with (A) Mitotracker orange (red) or (B) 
Lysotracker (red). Zoomed sections are shown as insets. Scale bars = 20 µm.  
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Figure 3 One-photon-induced PS activities of complexes 1 and 2. (A) Survival of 
HeLa cells pre-incubated for 2 or 24 h with complexes 1 or 2 +/- light. (B) Anexin V 
staining in HeLa cells (C) Survival of bladder (EJ), osteosarcoma (U2OS), melanoma 
(A375) and colorectal (HCT116) cancer cells 1 +/- light treatment. 
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Figure 4 Two-photon-induced PS activity of 1. HeLa cells treated with 1 or DMSO 
2 h before irradiation of a central square with 760 nm multiphoton laser. After 24h 
cells were stained with markers for apoptosis (Annexin V Ð red) and cell death 
(propidium iodide - green). All images are 450x450 µm except those in the 0 mW 
column which are 900x900 µm. 
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under 1-photon irradiation (405 nm) with photoindexes of up to >555. Remarkably 1 
also displays high PS activity under NIR two-photon excitation (760 nm) indicating 
potential future clinical application.  
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